Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody

Gerald L Denardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P McGahan, Stanley L. Mills, Sui Shen

Research output: Contribution to journalArticle

99 Scopus citations


Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.

Original languageEnglish (US)
Pages (from-to)239-254
Number of pages16
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Fingerprint Dive into the research topics of 'Low-dose, fractionated radioimmunotherapy for B-cell malignancies using <sup>131</sup>I-LYM-1 antibody'. Together they form a unique fingerprint.

  • Cite this

    Denardo, G. L., DeNardo, S. J., Lamborn, K. R., Goldstein, D. S., Levy, N. B., Lewis, J. P., O'Grady, L. F., Raventos, A., Kroger, L. A., Macey, D. J., McGahan, J. P., Mills, S. L., & Shen, S. (1998). Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody. Cancer Biotherapy and Radiopharmaceuticals, 13(4), 239-254.